Last updated: April 2026
Pinealon is a synthetic EDR tripeptide (Glu-Asp-Arg) from Russia's St. Petersburg Institute of Bioregulation and Gerontology. Designed to mimic natural cerebral cortex peptides, it's studied for neuroprotection, cognitive aging, and antioxidant support in the brain. Part of the same bioregulator family as Epithalon.
The bioregulator peptide theory: short peptides derived from specific organs "reset" the gene expression patterns of the same organ type. Pinealon's EDR sequence is designed to target brain tissue.
Bioregulator peptides are theorized to interact with chromatin/DNA directly, influencing gene expression in a tissue-specific manner. The EDR sequence of Pinealon is thought to bind to specific DNA promoter regions in brain cells, upregulating genes associated with neuroprotection and antioxidant defense. This is based on work by Khavinson et al. from the St. Petersburg Institute.
Published studies show Pinealon reduces oxidative stress markers in brain tissue models. It appears to upregulate superoxide dismutase (SOD) and catalase activity — the brain's primary antioxidant enzymes. Neuronal cultures exposed to oxidative stress showed reduced apoptosis with Pinealon treatment (Fedoreyeva et al., 2011).
Despite being primarily a "cerebral cortex" peptide, Pinealon appears to influence the melatonin synthesis pathway. Many users in Russian clinical observations reported improved sleep quality. The hypothesized mechanism: by supporting pineal-cortex communication, Pinealon may help normalize circadian melatonin rhythms that decline with aging.
In neurotoxicity models (ischemia, oxidative damage), Pinealon reduced neuronal cell death. Studies from Russian research groups reported decreased caspase activation and maintained mitochondrial membrane potential in neurons treated with Pinealon. This is the mechanistic basis for its proposed use in neurodegenerative aging and stroke recovery.
Evidence is primarily from Russian research groups. Western replication is limited. Methodology quality varies across publications.
Based on Russian clinical protocols from the St. Petersburg Institute and community use reports. Pinealon is available as injectable or intranasal formulations.
5–10mg/day for 10 days. Subcutaneous or intramuscular injection. The Russian clinical protocol is 10 consecutive days, then a break of several months before repeating. Most community users do this cycle 1–2 times per year. Reconstitute in bacteriostatic water.
10–20mg/day for 10 days. Intranasal administration delivers peptides directly to the CNS via olfactory transport — potentially increasing brain bioavailability vs. subcutaneous. Uses a nasal spray formulation. Dose is higher than injectable to compensate for mucosal absorption variability.
The bioregulator protocol emphasizes cycles because the mechanism is epigenetic — you're not trying to maintain blood levels, you're triggering gene expression changes that then persist. A 10-day cycle provides the stimulus; the effect continues for weeks to months afterward. This differs fundamentally from peptides like BPC-157 that require sustained tissue levels.
The most common bioregulator combination is Pinealon (brain) + Epithalon (pineal/systemic). They address complementary aspects of aging — Epithalon for telomere support and melatonin production, Pinealon for cortical neuroprotection. See our dedicated Pinealon-Epithalon synergy page for the full protocol.
Based on Russian study reports and community use. Pinealon has a favorable safety profile — the main risks are those common to all injectable research peptides.
Third-party HPLC tested with published COAs. One of the most established research peptide vendors.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Evidence-backed neuroprotective supplements commonly used alongside bioregulator peptide protocols.
Pinealon is not approved by the FDA or EMA. This content is for educational purposes only and does not constitute medical advice. Consult a physician before using any research peptide. HighPeptides does not recommend self-administration of unapproved compounds.